Promising 2022; even the softer 2023 guidance isn’t a worry
20/03/23 -"The positive recommendation is reiterated, underpinned by the firm’s strong pipeline, healthy progress on clinical trials and the promising market opportunities. While the stock has been under ..."
Pages
49
Language
English
Published on
20/03/23
You may also be interested by these reports :
25/03/24
Perfect execution of capacity ramp-up key for meeting targets – TP increased to CHF 81 (from CHF 75) – Reduce reiterated
21/03/24
BioNTech reported weaker than expected FY23 sales figures (-17.7%), explained by the structure of the partnering deal with Pfizer. However, investors ...
20/03/24
FDA approves TRYVIO (aprocitentan) for hypertension
19/03/24
Family controlled UCB (ADD; Belgium) has been one of the strongest performing pharma stocks (+36% in the share price) in 2024. While the recent surge ...